broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K71847383-001-12-5
|
ACH-000879
|
MFE296_ENDOMETRIUM
|
HTS002
| 1 | 2.122352 | -0.022826 | -0.026964 | 1.677789 | 8,415,092.899292 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000879
|
BRD-K71847383-001-12-5
|
ACH-000320
|
PSN1_PANCREAS
|
HTS002
| 1 | 1.325174 | -0.237504 | -0.147274 | 1.2403 | 9.643742 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000320
|
BRD-K71847383-001-12-5
|
ACH-001145
|
OC316_OVARY
|
HTS002
| 1 | 2.08935 | -0.302937 | 0.193893 | 1.472333 | 0.027767 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-001145
|
BRD-K71847383-001-12-5
|
ACH-000873
|
KYSE270_OESOPHAGUS
|
HTS002
| 1 | 1.31182 | -0.209393 | -0.00546 | 1.20716 | 2.654701 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000873
|
BRD-K71847383-001-12-5
|
ACH-000855
|
KYSE150_OESOPHAGUS
|
HTS002
| 1 | 1.369799 | -0.27753 | 0.132818 | 1.229332 | 0.588904 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000855
|
BRD-K71847383-001-12-5
|
ACH-000913
|
ESS1_ENDOMETRIUM
|
HTS002
| 1 | 2.433246 | -1.435943 | 0.168739 | 1.130378 | 0.001172 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000913
|
BRD-K71847383-001-12-5
|
ACH-000558
|
A172_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 1.78623 | 0.074955 | -0.029545 | 1.43674 | 0.003867 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000558
|
BRD-K71847383-001-12-5
|
ACH-000593
|
BC3C_URINARY_TRACT
|
HTS002
| 1 | 1.949354 | -0.192403 | 0.174755 | 1.328064 | 0.002247 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000593
|
BRD-K71847383-001-12-5
|
ACH-000488
|
TE11_OESOPHAGUS
|
HTS002
| 1 | 1.43101 | -0.220304 | 0.098313 | 1.200396 | 0.038911 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000488
|
BRD-K71847383-001-12-5
|
ACH-000832
|
CAL27_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 1.80839 | -0.098703 | -0.098915 | 1.335735 | 0.002288 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000832
|
BRD-K71847383-001-12-5
|
ACH-000781
|
NCIH2023_LUNG
|
HTS002
| 1 | 1.96334 | -0.157777 | 0.128698 | 1.467798 | 0.053276 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000781
|
BRD-K71847383-001-12-5
|
ACH-000137
|
8MGBA_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 4.750272 | 0.303556 | -0.111814 | 1.113997 | 20,095.432688 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000137
|
BRD-K71847383-001-12-5
|
ACH-000632
|
HS944T_SKIN
|
HTS002
| 1 | 2.144612 | -0.175569 | 0.328183 | 1.503386 | 0.018135 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000632
|
BRD-K71847383-001-12-5
|
ACH-000319
|
MPP89_PLEURA
|
HTS002
| 1 | 1.542258 | -0.055698 | -0.121322 | 1.379969 | 366,459.712136 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000319
|
BRD-K71847383-001-12-5
|
ACH-000630
|
YD8_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 1.894104 | -0.33901 | 0.145696 | 1.387071 | 0.029701 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000630
|
BRD-K71847383-001-12-5
|
ACH-000266
|
SNU213_PANCREAS
|
HTS002
| 1 | 2.057154 | -0.020719 | 0.005638 | 1.535763 | 0.290571 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000266
|
BRD-K71847383-001-12-5
|
ACH-000047
|
GCIY_STOMACH
|
HTS002
| 1 | 0.982869 | 1.297144 | -0.097755 | 0.99094 | 0.058964 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000047
|
BRD-K71847383-001-12-5
|
ACH-000273
|
SF539_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 2.102617 | -0.016699 | -0.009315 | 1.555969 | 0.215165 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000273
|
BRD-K71847383-001-12-5
|
ACH-000682
|
SNU1066_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 0.599211 | -0.323113 | -0.10721 | 0.882446 | 0.003114 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000682
|
BRD-K71847383-001-12-5
|
ACH-000359
|
MG63_BONE
|
HTS002
| 1 | 0.733572 | -0.693434 | 0.122409 | 0.905373 | 0.017 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000359
|
BRD-K71847383-001-12-5
|
ACH-000846
|
FADU_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 0.689928 | 0.251677 | 0.176607 | 0.84035 | 0.059922 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000846
|
BRD-K71847383-001-12-5
|
ACH-000804
|
NB1_AUTONOMIC_GANGLIA
|
HTS002
| 1 | 1.011043 | 0.151074 | -0.005991 | 1.005126 | 0.210465 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000804
|
BRD-K71847383-001-12-5
|
ACH-000609
|
SF126_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 0.802225 | -0.085226 | -0.080794 | 0.874109 | 61.342199 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000609
|
BRD-K71847383-001-12-5
|
ACH-000974
|
SNGM_ENDOMETRIUM
|
HTS002
| 1 | 3.03257 | 1.655876 | -0.193973 | 1.000528 | 273.23 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000974
|
BRD-K71847383-001-12-5
|
ACH-000987
|
MEWO_SKIN
|
HTS002
| 1 | 1.007962 | -0.263855 | -0.12153 | 1.005038 | 0.802389 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000987
|
BRD-K71847383-001-12-5
|
ACH-000787
|
LXF289_LUNG
|
HTS002
| 1 | 1.510421 | -0.274899 | 0.056012 | 1.096079 | 0.000201 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000787
|
BRD-K71847383-001-12-5
|
ACH-000561
|
TT_OESOPHAGUS
|
HTS002
| 1 | 1.247121 | -0.019809 | 0.005774 | 1.121053 | 0.010051 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000561
|
BRD-K71847383-001-12-5
|
ACH-000212
|
CAL120_BREAST
|
HTS002
| 1 | 1.172737 | 5.356881 | -0.08334 | 1.111354 | 0.019195 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000212
|
BRD-K71847383-001-12-5
|
ACH-000753
|
JMSU1_URINARY_TRACT
|
HTS002
| 1 | 1.97744 | 0.356437 | -0.081285 | 1.369569 | 0.436467 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000753
|
BRD-K71847383-001-12-5
|
ACH-000305
|
ECGI10_OESOPHAGUS
|
HTS002
| 1 | 1.353783 | -0.178115 | -0.026861 | 1.184637 | 0.131692 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000305
|
BRD-K71847383-001-12-5
|
ACH-000138
|
CFPAC1_PANCREAS
|
HTS002
| 1 | 1.179622 | 0.005991 | -0.034276 | 1.088015 | 62.186931 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000138
|
BRD-K71847383-001-12-5
|
ACH-000250
|
KMRC20_KIDNEY
|
HTS002
| 1 | 1.137318 | 0.402542 | 0.026051 | 1.033079 | 2.893364 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000250
|
BRD-K71847383-001-12-5
|
ACH-000856
|
CAL51_BREAST
|
HTS002
| 1 | 1.570118 | -0.391067 | 0.161732 | 1.320316 | 0.176486 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000856
|
BRD-K71847383-001-12-5
|
ACH-000046
|
ACHN_KIDNEY
|
HTS002
| 1 | 1.973399 | 0.203092 | -0.177348 | 1.307926 | 4.63 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000046
|
BRD-K71847383-001-12-5
|
ACH-000878
|
HCC15_LUNG
|
HTS002
| 1 | 1.276811 | 0.423643 | -0.19365 | 1.161206 | 0.027591 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000878
|
BRD-K71847383-001-12-5
|
ACH-000766
|
NCIH1648_LUNG
|
HTS002
| 1 | 1.356497 | 0.251445 | -0.144285 | 1.179586 | 0.073066 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000766
|
BRD-K71847383-001-12-5
|
ACH-000666
|
NCIH1355_LUNG
|
HTS002
| 1 | 2.688037 | 0.002436 | -0.000447 | 1.83814 | 23.774893 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000666
|
BRD-K71847383-001-12-5
|
ACH-000014
|
HS294T_SKIN
|
HTS002
| 1 | 1.736533 | -3.519942 | 0.209834 | 1.352513 | 0.063481 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000014
|
BRD-K71847383-001-12-5
|
ACH-000701
|
RMUGS_OVARY
|
HTS002
| 1 | 2.306763 | -0.334336 | 0.066222 | 1.319396 | 0.001413 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000701
|
BRD-K71847383-001-12-5
|
ACH-000884
|
MDAMB435S_SKIN
|
HTS002
| 1 | 1.495186 | -1.412309 | -0.06372 | 1.184753 | 0.022707 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000884
|
BRD-K71847383-001-12-5
|
ACH-000504
|
SNB75_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 1.626684 | -9.720646 | 0.242547 | 1.399741 | 0.297728 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000504
|
BRD-K71847383-001-12-5
|
ACH-000502
|
TCCPAN2_PANCREAS
|
HTS002
| 1 | 1.556409 | -0.741207 | 0.185838 | 1.191476 | 0.015475 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000502
|
BRD-K71847383-001-12-5
|
ACH-000886
|
NCIH2009_LUNG
|
HTS002
| 1 | 1.933061 | -0.603979 | -0.017778 | 1.443687 | 0.059969 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000886
|
BRD-K71847383-001-12-5
|
ACH-000035
|
NCIH1650_LUNG
|
HTS002
| 1 | 1.648817 | -2.658655 | 0.307478 | 1.386549 | 0.197893 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000035
|
BRD-K71847383-001-12-5
|
ACH-000661
|
WM1799_SKIN
|
HTS002
| 1 | 1.137175 | -0.219573 | -0.130107 | 1.090688 | 2.151031 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000661
|
BRD-K71847383-001-12-5
|
ACH-000391
|
MHHES1_BONE
|
HTS002
| 1 | 1.101463 | 0.146963 | -0.022932 | 1.064826 | 0.001372 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000391
|
BRD-K71847383-001-12-5
|
ACH-000843
|
HARA_LUNG
|
HTS002
| 1 | 1.792085 | -2.132069 | 0.632434 | 1.438149 | 0.130869 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000843
|
BRD-K71847383-001-12-5
|
ACH-000711
|
JIMT1_BREAST
|
HTS002
| 1 | 1.812952 | -0.080722 | -0.057074 | 1.420198 | 0.182304 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000711
|
BRD-K71847383-001-12-5
|
ACH-000232
|
U251MG_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 1.903037 | -0.228779 | 0.404941 | 1.342351 | 0.007312 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000232
|
BRD-K71847383-001-12-5
|
ACH-000060
|
PANC1005_PANCREAS
|
HTS002
| 1 | 2.792043 | -0.617184 | 0.248363 | 1.289292 | 0.001361 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000060
|
BRD-K71847383-001-12-5
|
ACH-000736
|
SNU601_STOMACH
|
HTS002
| 1 | 1.271749 | 0.088243 | -0.021303 | 1.159139 | 0.001462 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000736
|
BRD-K71847383-001-12-5
|
ACH-000809
|
KYSE410_OESOPHAGUS
|
HTS002
| 1 | 1.422825 | -0.371051 | -0.062547 | 1.225799 | 0.123933 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000809
|
BRD-K71847383-001-12-5
|
ACH-000747
|
NCIH1703_LUNG
|
HTS002
| 1 | 2.042603 | -0.059189 | -0.013878 | 1.39679 | 0.00002 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000747
|
BRD-K71847383-001-12-5
|
ACH-000364
|
U2OS_BONE
|
HTS002
| 1 | 1.65522 | -0.289141 | 0.046196 | 1.307502 | 0.04774 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000364
|
BRD-K71847383-001-12-5
|
ACH-000679
|
OE19_OESOPHAGUS
|
HTS002
| 1 | 1.813996 | -0.089484 | 0.048039 | 1.378985 | 0.016337 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000679
|
BRD-K71847383-001-12-5
|
ACH-000985
|
LS411N_LARGE_INTESTINE
|
HTS002
| 1 | 1.231335 | -0.001359 | -0.010766 | 1.116323 | 326.183562 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000985
|
BRD-K71847383-001-12-5
|
ACH-000441
|
SH4_SKIN
|
HTS002
| 1 | 1.372867 | 0.145105 | -0.105724 | 1.181955 | 0.110285 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000441
|
BRD-K71847383-001-12-5
|
ACH-001113
|
LC1SQSF_LUNG
|
HTS002
| 1 | 1.658567 | 0.116132 | -0.120648 | 1.312522 | 0.192249 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-001113
|
BRD-K71847383-001-12-5
|
ACH-000620
|
JHH1_LIVER
|
HTS002
| 1 | 1.752969 | -0.254885 | 0.123659 | 1.285903 | 0.009009 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000620
|
BRD-K71847383-001-12-5
|
ACH-000853
|
NCIH661_LUNG
|
HTS002
| 1 | 1.689289 | -0.008143 | -0.006801 | 1.347048 | 0.433205 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000853
|
BRD-K71847383-001-12-5
|
ACH-000102
|
GMS10_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 1.405265 | -0.555669 | -0.07751 | 1.141014 | 0.013984 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000102
|
BRD-K71847383-001-12-5
|
ACH-000648
|
NCIH28_PLEURA
|
HTS002
| 1 | 1.501956 | -0.024347 | -0.00387 | 1.239972 | 0.002115 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000648
|
BRD-K71847383-001-12-5
|
ACH-001239
|
WM2664_SKIN
|
HTS002
| 1 | 1.559267 | 0.072719 | -0.011224 | 1.344977 | 0.000105 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-001239
|
BRD-K71847383-001-12-5
|
ACH-001321
|
TT_THYROID
|
HTS002
| 1 | 1.534746 | 0.099931 | -0.047879 | 1.238696 | 0.702783 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-001321
|
BRD-K71847383-001-12-5
|
ACH-000279
|
EWS502_BONE
|
HTS002
| 1 | 1.407583 | -0.059093 | -0.037438 | 1.331711 | 6,277,572,691.02502 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000279
|
BRD-K71847383-001-12-5
|
ACH-000172
|
TM87_SOFT_TISSUE
|
HTS002
| 1 | 1.235192 | -0.155161 | 0.036348 | 1.146125 | 2.197803 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000172
|
BRD-K71847383-001-12-5
|
ACH-001128
|
MON_SOFT_TISSUE
|
HTS002
| 1 | 2.229657 | 0.504519 | 0.234653 | 1.376345 | 0.791739 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-001128
|
BRD-K71847383-001-12-5
|
ACH-000437
|
SW1088_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 1.551767 | 0.003152 | -0.057111 | 1.24203 | 749,079,266,429,778,000,000,000,000,000,000 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000437
|
BRD-K71847383-001-12-5
|
ACH-000735
|
PECAPJ49_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 1.66728 | 0.162644 | 0.030533 | 1.270144 | 0.941598 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000735
|
BRD-K71847383-001-12-5
|
ACH-000643
|
HDQP1_BREAST
|
HTS002
| 1 | 1.300983 | -0.002252 | -0.090685 | 1.229564 | 124,718,079,427,031,990,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000643
|
BRD-K71847383-001-12-5
|
ACH-000207
|
DETROIT562_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 1.573073 | -0.227289 | -0.085698 | 1.275321 | 0.053489 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000207
|
BRD-K71847383-001-12-5
|
ACH-000456
|
BCPAP_THYROID
|
HTS002
| 1 | 0.793404 | -0.072785 | 0.003761 | 0.886931 | 1.088019 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000456
|
BRD-K71847383-001-12-5
|
ACH-000260
|
SKNAS_AUTONOMIC_GANGLIA
|
HTS002
| 1 | 2.465575 | -0.246002 | 0.037561 | 1.330327 | 0.000309 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000260
|
BRD-K71847383-001-12-5
|
ACH-000019
|
MCF7_BREAST
|
HTS002
| 1 | 3.480451 | -1.351019 | 0.338182 | 1.117433 | 0.000546 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000019
|
BRD-K71847383-001-12-5
|
ACH-000582
|
COLO741_SKIN
|
HTS002
| 1 | 1.331186 | -0.036785 | -0.024406 | 1.161265 | 0.018786 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000582
|
BRD-K71847383-001-12-5
|
ACH-000990
|
HEC108_ENDOMETRIUM
|
HTS002
| 1 | 1.866183 | -0.323197 | 0.076346 | 1.466818 | 0.139222 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000990
|
BRD-K71847383-001-12-5
|
ACH-000374
|
HCC1143_BREAST
|
HTS002
| 1 | 1.337186 | -3.774497 | 0.205927 | 1.186465 | 0.130668 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000374
|
BRD-K71847383-001-12-5
|
ACH-000759
|
MDAMB175VII_BREAST
|
HTS002
| 1 | 31.004322 | 6.598629 | -0.050817 | 1 | 1,518,751.086006 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000759
|
BRD-K71847383-001-12-5
|
ACH-000417
|
PANC0813_PANCREAS
|
HTS002
| 1 | 1.328283 | -0.373733 | 0.163977 | 1.144888 | 0.035322 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000417
|
BRD-K71847383-001-12-5
|
ACH-000308
|
EFO21_OVARY
|
HTS002
| 1 | 2.114597 | -0.95661 | 0.00352 | 1.049944 | 0.000306 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000308
|
BRD-K71847383-001-12-5
|
ACH-000991
|
SNU81_LARGE_INTESTINE
|
HTS002
| 1 | 1.948835 | 0.106052 | -0.017725 | 1.428424 | 0.509029 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000991
|
BRD-K71847383-001-12-5
|
ACH-000948
|
2313287_STOMACH
|
HTS002
| 1 | 1.778375 | -0.263089 | -0.135096 | 1.200618 | 0.000864 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000948
|
BRD-K71847383-001-12-5
|
ACH-000481
|
NCIH2170_LUNG
|
HTS002
| 1 | 2.119629 | -0.191805 | -0.016462 | 1.258869 | 0.0001 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000481
|
BRD-K71847383-001-12-5
|
ACH-000771
|
BICR56_UPPER_AERODIGESTIVE_TRACT
|
HTS002
| 1 | 1.817293 | -0.140247 | 0.00367 | 1.258888 | 0.000266 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000771
|
BRD-K71847383-001-12-5
|
ACH-000159
|
OSRC2_KIDNEY
|
HTS002
| 1 | 1.554384 | 0.348691 | -0.046052 | 1.115549 | 7.610348 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000159
|
BRD-K71847383-001-12-5
|
ACH-000929
|
NCIH2110_LUNG
|
HTS002
| 1 | 1.318948 | -0.00962 | -0.017966 | 1.184178 | 9,915,028,688,315.97 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000929
|
BRD-K71847383-001-12-5
|
ACH-000118
|
HUPT3_PANCREAS
|
HTS002
| 1 | 1.62972 | -0.031329 | -0.031623 | 1.322421 | 0.363028 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000118
|
BRD-K71847383-001-12-5
|
ACH-000482
|
RERFLCKJ_LUNG
|
HTS002
| 1 | 1.5697 | -0.062958 | -0.00052 | 1.2659 | 0.009258 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000482
|
BRD-K71847383-001-12-5
|
ACH-000352
|
HCC1428_BREAST
|
HTS002
| 1 | 1.347118 | -0.138262 | -0.051449 | 1.229072 | 11.219077 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000352
|
BRD-K71847383-001-12-5
|
ACH-000235
|
PANC0403_PANCREAS
|
HTS002
| 1 | 1.824181 | -0.243612 | -0.027092 | 1.393905 | 0.052171 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000235
|
BRD-K71847383-001-12-5
|
ACH-000900
|
NCIH23_LUNG
|
HTS002
| 1 | 1.497804 | -2.670336 | 0.277943 | 1.275023 | 0.129995 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000900
|
BRD-K71847383-001-12-5
|
ACH-000479
|
KNS81_CENTRAL_NERVOUS_SYSTEM
|
HTS002
| 1 | 1.567524 | -0.043777 | -0.08634 | 1.294179 | 0.421002 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000479
|
BRD-K71847383-001-12-5
|
ACH-000401
|
COLO800_SKIN
|
HTS002
| 1 | 1.237604 | -1.558154 | 0.038189 | 1.145062 | 0.228727 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000401
|
BRD-K71847383-001-12-5
|
ACH-000276
|
HCC38_BREAST
|
HTS002
| 1 | 1.528225 | -0.603912 | 0.047539 | 1.191256 | 0.01726 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000276
|
BRD-K71847383-001-12-5
|
ACH-000724
|
HT1376_URINARY_TRACT
|
HTS002
| 1 | 3.662735 | 0.270642 | -0.148154 | 1.146261 | 7,074.457907 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000724
|
BRD-K71847383-001-12-5
|
ACH-000092
|
NCIH2452_PLEURA
|
HTS002
| 1 | 2.047424 | -0.277374 | 0.0234 | 1.180893 | 0.000139 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000092
|
BRD-K71847383-001-12-5
|
ACH-000890
|
SW1271_LUNG
|
HTS002
| 1 | 1.731201 | -0.529288 | 0.156301 | 1.336417 | 0.049705 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000890
|
BRD-K71847383-001-12-5
| null | null |
HTS002
| 1 | 1.573798 | -0.632507 | -0.001141 | 1.389931 | 0.552499 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| false |
ACH-000539_FAILED_STR
|
BRD-K71847383-001-12-5
|
ACH-000800
|
NCIH446_LUNG
|
HTS002
| 1 | 1.422689 | -3.980899 | 0.225771 | 1.072802 | 0.003246 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000800
|
BRD-K71847383-001-12-5
|
ACH-000899
|
WM88_SKIN
|
HTS002
| 1 | 1.969301 | -0.376862 | 0.446775 | 1.473547 | 0.066992 | null |
cytarabine
|
ribonucleotide reductase inhibitor
|
POLA1, POLB, POLD1, POLE
|
hematologic malignancy
|
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
|
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
|
Launched
| true |
ACH-000899
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.